Get the Stockscreener App
99.06
1.21%
1.185
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $99.06, with a volume of 4.78M.
It is up +1.21% in the last 24 hours and down -6.12% over the past month.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$97.88
Open:
$97.87
24h Volume:
4.78M
Relative Volume:
0.54
Market Cap:
$129.74B
Revenue:
$28.73B
Net Income/Loss:
$5.97B
P/E Ratio:
20.86
EPS:
4.75
Net Cash Flow:
$10.37B
1W Performance:
-7.02%
1M Performance:
-6.12%
6M Performance:
+1.19%
1Y Performance:
+51.33%
1-Day Range:
$97.33
$99.70
1-Week Range:
$97.33
$105.86
52-Week Range:
$62.07
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
99.03 | 129.74B | 28.73B | 5.97B | 10.37B | 4.75 |
|
LLY
Lilly Eli Co
|
773.87 | 696.19B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
157.05 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
188.13 | 342.31B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
67.22 | 289.25B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
111.57 | 224.07B | 53.22B | 12.86B | 14.85B | 6.39 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Fighting the World’s Most Devastating Diseases Is the Focus of This Installment of “The Centrifuge Sessions - CSRwire
Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 - BioSpace
Gilead (GILD): Livdelzi Shows Promising Results for PBC Treatment | GILD Stock News - GuruFocus
GILD: Promising Results from Gilead's Bulevirtide Study for Chronic Hepatitis Delta | GILD Stock News - GuruFocus
Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy - GuruFocus
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment - Business Wire
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead (GILD) Sees Bearish Options Activity with Heavy Put Trading | GILD Stock News - GuruFocus
Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions" - marketscreener.com
Gilead: Sure, Why Not, But Not The CDRs (GILD:CA) - Seeking Alpha
What Are Wall Street Analysts' Target Price for Gilead Sciences Stock? - Nasdaq
Mizuho Adjusts Price Target on Gilead Sciences to $117 From $100, Maintains Outperform Rating - marketscreener.com
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term - Yahoo
What Are Wall Street Analysts' Target Price For Gilead Sciences Stock? - Barchart.com
Gilead (GILD) Sees 24% Stock Surge Amid Tariff Resilience - GuruFocus
Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
Here's What to Expect From Gilead Sciences’ Next Earnings Report - MSN
Struggling Peninsula biotech with Gilead lineage is latest purchase for activist investor - The Business Journals
Gilead Sciences (GILD): A Promising Pick Amid Economic Uncertain - GuruFocus
June 13th Options Now Available For Gilead Sciences (GILD) - Nasdaq
Gilead Agrees To Pay $202M To Settle Alleged Speaker Kickback Claims In FCA Suit - Law360
Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors - MSN
Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Gilead Sciences Stock Falls as Slumping COVID-19, Cancer Drug Sales Hit Revenue - MSN
BlackRock, Inc. Reduces Stake in Gilead Sciences Inc. - GuruFocus
Gilead Sciences: Hold Rating Maintained Amid Near-Term Challenges and Limited Growth Prospects - TipRanks
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? - Yahoo Finance
Gilead Will Pay $202M In DOJ Deal Over Drug Kickbacks - Law360
Gilead Sciences to pay $202 million in US settlement over HIV drug kickbacks - Reuters
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis - BioSpace
Gilead Sciences to Present at Upcoming Investor Conferences - BioSpace
Gilead enters $202M settlement to resolve US government's long-running HIV kickbacks probe - Fierce Pharma
Gilead will pay $202 million to settle charges of paying kickbacks to docs for boosting HIV drug sales - statnews.com
Sector Update: Health Care Stocks Gain Late Afternoon - marketscreener.com
Gilead Sciences Coughs Up $202 Million in Kickback Scandal Settlement Over HIV Drug Prescriptions in New York - Hoodline
Gilead (GILD) Settles Fraud Case with $202 Million Agreement | G - GuruFocus
Gilead Sciences (GILD) Settles DOJ Kickback Allegations for $202M - GuruFocus
Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit - marketscreener.com
Gilead in $202M settlement with DoJ over kickbacks to doctors - Seeking Alpha
Gilead Sciences (GILD) Agrees to Pay $202 Million Over Doctor Payments - Bloomberg.com
Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress - simplywall.st
Gilead to pay $202 million to settle doctor kickback claims related to HIV drug prescriptions - CNBC
Gilead to Present Latest Advancements Across Primary Biliary Cho - GuruFocus
Gilead presents new liver disease treatment data at EASL Congress By Investing.com - Investing.com India
Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States - Yahoo Finance
Gilead Sciences (GILD) to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis - StreetInsider
Biotech Powerhouse: Ex-Gilead CMO Merdad Parsey Strengthens Ardelyx Board with 25-Year Expertise - Stock Titan
Cancer Immunotherapy Market to Witness Massive Growth by 2032 | - openPR.com
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs - GlobeNewswire Inc.
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.63%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):